CurrentCignaPolicy IP0343

Ophthalmology - Pilocarpine 1.25%

Customize your policy alerts

Sign up for Cigna Policy IP0343 alerts

Get alerted when Policy IP0343 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

This policy governs coverage of Vuity (pilocarpine 1.25% ophthalmic solution) and generic pilocarpine 1.25% for health benefit plans administered by Cigna. It determines medical necessity and reimbursement for provider-submitted claims, subject to the applicable benefit plan, laws, and individual clinical circumstances.

Policy Summary

PayerCigna

PolicyOphthalmology - Pilocarpine 1.25%

Policy CodePolicy IP0343

Change TypeMaterial update

Effective DateOct 15, 2026

Last ReviewSep 10, 2026

Next Review DateN/A

Key ActionUse covered diagnosis and procedure codes when submitting claims.

SourceLink

POLICY UPDATE CHANGES

Generic pilocarpine 1.25% ophthalmic solution was added to the policy.

The policy title was updated from Pilocarpine 1.25% Ophthalmic to Ophthalmology - Pilocarpine 1.25%.

2 productsProducts identified

AdultsFDA-approved population

Not medically necessaryCoverage stance

Any usePolicy scope

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentCignaPolicy IP0343

Ophthalmology - Pilocarpine 1.25%

Customize your policy alerts

Sign up for Cigna Policy IP0343 alerts

Get alerted when Policy IP0343 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerCigna

PolicyOphthalmology - Pilocarpine 1.25%

Policy CodePolicy IP0343

Change TypeMaterial update

Effective DateOct 15, 2026

Last ReviewSep 10, 2026

Next Review DateN/A

Key ActionUse covered diagnosis and procedure codes when submitting claims.

SourceLink

POLICY UPDATE CHANGES

Generic pilocarpine 1.25% ophthalmic solution was added to the policy.

The policy title was updated from Pilocarpine 1.25% Ophthalmic to Ophthalmology - Pilocarpine 1.25%.

2 productsProducts identified

AdultsFDA-approved population

Not medically necessaryCoverage stance

Any usePolicy scope

Coverage Criteria

Not Medically Necessary

Pilocarpine 1.25% is considered not medically necessary for any use.

Any use: Pilocarpine 1.25% use, including use for presbyopia, is considered not medically necessary.

The list of uses is not necessarily all-inclusive.

Pilocarpine 1.25% for the treatment of presbyopia is not medically necessary. Although the drug is FDA approved for presbyopia in adults, presbyopia results from the normal aging process rather than an illness, injury, disease, or symptom of one.

Any use of pilocarpine 1.25%, including treatment of presbyopia, is considered not medically necessary. The policy’s examples are not necessarily all-inclusive.

Provider Actions

Billing Rule

Use covered codes and diagnoses

Submit services with the covered diagnosis and/or procedure codes required under the applicable Coverage Policy. Claims submitted without covered code(s), or for conditions or diagnoses not covered under the policy, will be denied as not covered.

Denial Risk

Presbyopia and other uses

Do not expect coverage for pilocarpine 1.25% when billed for presbyopia or any other use identified by the policy. Such use is considered not medically necessary and may be denied.

Background

Pilocarpine 1.25% ophthalmic solution is a cholinergic muscarinic receptor agonist indicated for the treatment of presbyopia in adults.

Definitions

Presbyopia

DefinitionPresbyopia is the irreversible loss of the eye’s accommodative ability due to aging.

OnsetThe condition develops gradually as a natural result of aging.

Common initial symptomGradual-onset blurred near vision is often the first presenting symptom.

Other characteristicsCommonly experienced features include squinting, eye-strain headaches, increased light requirements, and the need to work from progressively greater distances.

Typical progressionThe average age at which symptoms are first reported is between 42 and 44 years; complete loss of accommodation typically occurs between ages 50 and 55.